Cargando…

The Effect of Temperature on the Stability of PCSK-9 Monoclonal Antibody: An Experimental Study

Mostrar otras versiones (1)

Background: PCSK9 monoclonal antibody lowers plasma PCSK9 and LDL-cholesterol levels. The manufacturers recommend drug storage at 2–8°C, and not above 25°C. This study aimed to investigate drug stability at various temperatures that this drug could be exposed to during medication handling and transp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kongmalai, Tanawan, Chuanchaiyakul, Nalinee, Tansit, Tunsuda, Sripatumtong, Chattip, Srinoulprasert, Yuttana, Klinsukon, Nareerak, Thongtang, Nuntakorn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Cardiovascular Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089558/ http://dx.doi.org/10.1210/jendso/bvab048.609

Ejemplares similares

The effect of temperature on the stability of PCSK-9 monoclonal antibody: an experimental study
por: Kongmalai, Tanawan, et al.
Publicado: (2021)

Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report
por: Kongmalai, Tanawan, et al.
Publicado: (2023)

Development and Evaluation of an In-House ELISA to Detect Anti-FcεR1α IgG Autoantibodies in Chronic Spontaneous Urticaria Patients
por: Sripatumtong, Chattip, et al.
Publicado: (2022)

2304. Incidence and Risk Factors for Herpes Zoster among Diabetes Patients at Siriraj Hospital; Results from a 10-year Cohort
por: Chuanchaiyakul, Nalinee, et al.
Publicado: (2019)

New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials
por: Kongmalai, Tanawan, et al.
Publicado: (2023)

SUN-580 PCSK9 and Lp(a): Association Between PCSK9 Level and Larger Apo(a) Isoform Size in African-Americans and Caucasians
por: Byambaa, Enkhmaa, et al.
Publicado: (2020)

SUN-573 Use of PCSK9 Inhibitors Post-Transplant
por: Matthews, Juliana, et al.
Publicado: (2020)

SUN-574 A1AT: Novel Inhibitor of Active PCSK9
por: Melendez, Quantil, et al.
Publicado: (2020)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

SAT-576 Possible Involvement of Thyroid Function in PCSK9 Inhibitor Therapy
por: Iwabuchi, Masayasu
Publicado: (2020)

FRI101 Marked Reduction In Severe Resistant Hypertriglyceridemia On PCSK9 Inhibitor
por: Kaul, Sabrina, et al.
Publicado: (2023)

Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials
por: Wong, Nathan D., et al.
Publicado: (2019)

Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
por: Zhang, Ruixing, et al.
Publicado: (2023)

The Effect of high temperature on the stability of basal insulin in a pen: a randomized controlled, crossover, equivalence trial
por: Kongmalai, Tanawan, et al.
Publicado: (2022)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials
por: Cao, Ye-Xuan, et al.
Publicado: (2018)

Physical activity to reduce PCSK9 levels
por: Tirandi, Amedeo, et al.
Publicado: (2022)

A rare case of ectopic ACTH syndrome caused by primary renal neuroendocrine tumor
por: Chunharojrith, Paweena, et al.
Publicado: (2021)

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
por: Xia, Xiao-dan, et al.
Publicado: (2021)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

Coexistence of Graves’ disease and unilateral functioning Struma ovarii: a case report
por: Sitasuwan, Tullaya, et al.
Publicado: (2015)

Efficacy of low- and moderate-intensity statins for achieving low- density lipoprotein cholesterol targets in Thai type 2 diabetic patients
por: Thongtang, Nuntakorn, et al.
Publicado: (2017)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
por: Chen, Hongzhen, et al.
Publicado: (2023)

Correlation Between Circulating PCSK9 Levels and Gestational Diabetes Mellitus in a Chinese Population
por: Wu, Yiming, et al.
Publicado: (2022)

Neoatherosclerosis in Sirolimus-Eluting Stents After Paclitaxel-Coated Ballooning Cannot Be Stabilized Despite PCSK9 Inhibitor Therapy
por: Miyoshi, Toru, et al.
Publicado: (2019)

Effects of PCSK9 inhibition on glucose metabolism and β-cell function in humans: a pilot study
por: Moffa, Simona, et al.
Publicado: (2023)

Clinical value of in vitro tests for the management of severe drug hypersensitivity reactions
por: Srinoulprasert, Yuttana, et al.
Publicado: (2020)

PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
por: EBioMedicine
Publicado: (2015)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

Impact of Obesity on Outcomes of Operable Breast Cancer: A Retrospective Cohort Study
por: Engkakul, Tanapat, et al.
Publicado: (2020)

Anti‐PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care
por: Descamps, Olivier S., et al.
Publicado: (2017)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
por: Wang, Shuai, et al.
Publicado: (2022)

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
por: Ma, Minglu, et al.
Publicado: (2023)

Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices
por: Thongtang, Nuntakorn, et al.
Publicado: (2022)

Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE(−/−) Mice
por: Jin, Ping, et al.
Publicado: (2021)

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
por: Gianazza, Erica, et al.
Publicado: (2023)

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
por: Ugovšek, Sabina, et al.
Publicado: (2022)

Effect of Thunbergia laurifolia Herbal Tea on Glucose Homeostasis in Healthy Volunteers: A Single-Arm Phase I Study
por: Preechasuk, Lukana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0evdglusv3bqqq0id3c8gbsjjg